Please login to the form below

Not currently logged in
Email:
Password:

Allergan acquires Vicept

Allergan has entered into an agreement to buy privately-owned Vicept Therapeutics

California-based pharmaceutical firm Allergan is set to acquire privately-owned Vicept Therapeutics for an undisclosed sum.

The agreement, which is expected to be finalised in the third quarter of 2011, includes a $75m cash upfront payment and up to $200m of milestone payments.

Dr Scott M Whitcup, executive vice president and chief scientific officer of Allergan, said: "The acquisition of Vicept Therapeutics will further enhance our dermatology research and development pipeline, and matches our corporate strategy and long-standing commitment to patients suffering from skin disorders."

Vicept Therapeutics' lead investigational product is V-101, a topical cream for the treatment of the erythema associated with rosacea, which has achieved positive results in two randomised, placebo-controlled phase II studies.

25th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics